Tempest Therapeutics, Inc. Selling, General and Administrative Expense
Tempest Therapeutics, Inc. (TPST) reported Selling, General and Administrative Expense of $4.18 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2018-11-09
- Tempest Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2018-09-30 was $4.18M, a 17.41% decline year-over-year.
- Tempest Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2018-06-30 was $2.65M, a 75.40% decline year-over-year.
- Tempest Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2018-03-31 was $4.22M, a 40.75% decline year-over-year.
- Tempest Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2017-12-31 was $4.81M, a 56.07% decline year-over-year.
- Tempest Therapeutics, Inc. selling, general and administrative expense for fiscal 2017 was $27.74M, a 43.64% decline from fiscal 2016.
- Tempest Therapeutics, Inc. selling, general and administrative expense for fiscal 2016 was $49.22M, a 4.60% decline from fiscal 2015.
- Tempest Therapeutics, Inc. selling, general and administrative expense for fiscal 2015 was $51.59M, a 97.31% increase from fiscal 2014.
- Tempest Therapeutics, Inc. selling, general and administrative expense for fiscal 2014 was $26.15M, a 96.14% increase from fiscal 2013.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2018-09-30 | $4.18M 10-Q · filed 2018-11-09 | $6.82M derived: sum of 2 quarters · filed 2018-11-09 | $11.04M 10-Q · filed 2018-11-09 | $15.85M derived: sum of 4 quarters · filed 2018-11-09 |
| 2018-06-30 | $2.65M 10-Q · filed 2018-08-09 | $6.87M 10-Q · filed 2018-08-09 | $11.68M derived: sum of 3 quarters · filed 2018-08-09 | $16.73M derived: sum of 4 quarters · filed 2018-11-09 |
| 2018-03-31 | $4.22M 10-Q · filed 2018-05-03 | $9.03M derived: sum of 2 quarters · filed 2018-05-03 | $14.09M derived: sum of 3 quarters · filed 2018-11-09 | $24.84M derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-12-31 | $4.81M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $9.87M derived: sum of 2 quarters · filed 2018-11-09 | $20.62M derived: sum of 3 quarters · filed 2018-11-09 | $27.74M 10-K · filed 2018-03-15 |
| 2017-09-30 | $5.06M 10-Q · filed 2018-11-09 | $15.81M derived: sum of 2 quarters · filed 2018-11-09 | $22.93M 10-Q · filed 2018-11-09 | $33.88M derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | $10.75M 10-Q · filed 2018-08-09 | $17.88M 10-Q · filed 2018-08-09 | $28.83M derived: sum of 3 quarters · filed 2018-08-09 | $41.44M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $7.13M 10-Q · filed 2018-05-03 | $18.08M derived: sum of 2 quarters · filed 2018-05-03 | $30.69M derived: sum of 3 quarters · filed 2018-05-03 | $41.90M derived: sum of 4 quarters · filed 2018-05-03 |
| 2016-12-31 | $10.95M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $23.56M derived: sum of 2 quarters · filed 2018-03-15 | $34.77M derived: sum of 3 quarters · filed 2018-03-15 | $49.22M 10-K · filed 2018-03-15 |
| 2016-09-30 | $12.61M 10-Q · filed 2017-11-02 | $23.82M derived: sum of 2 quarters · filed 2017-11-02 | $38.28M 10-Q · filed 2017-11-02 | $52.85M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-06-30 | $11.21M 10-Q · filed 2017-08-03 | $25.66M 10-Q · filed 2017-08-03 | $40.24M derived: sum of 3 quarters · filed 2018-03-15 | $53.15M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-03-31 | $14.45M 10-Q · filed 2017-05-09 | $29.03M derived: sum of 2 quarters · filed 2018-03-15 | $41.94M derived: sum of 3 quarters · filed 2018-03-15 | $55.00M derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-12-31 | $14.57M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $27.48M derived: sum of 2 quarters · filed 2018-03-15 | $40.55M derived: sum of 3 quarters · filed 2018-03-15 | $51.59M 10-K · filed 2018-03-15 |
| 2015-09-30 | $12.91M 10-Q · filed 2016-11-03 | $25.98M derived: sum of 2 quarters · filed 2016-11-03 | $37.02M 10-Q · filed 2016-11-03 | $48.04M derived: sum of 4 quarters · filed 2017-03-02 |
| 2015-06-30 | $13.07M 10-Q · filed 2016-08-04 | $24.11M 10-Q · filed 2016-08-04 | $35.13M derived: sum of 3 quarters · filed 2017-03-02 | $42.20M derived: sum of 4 quarters · filed 2017-03-02 |
| 2015-03-31 | $11.05M 10-Q · filed 2016-05-05 | $22.06M derived: sum of 2 quarters · filed 2017-03-02 | $29.14M derived: sum of 3 quarters · filed 2017-03-02 | $34.20M derived: sum of 4 quarters · filed 2017-03-02 |
| 2014-12-31 | $11.02M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $18.09M derived: sum of 2 quarters · filed 2017-03-02 | $23.15M derived: sum of 3 quarters · filed 2017-03-02 | $26.15M 10-K · filed 2017-03-02 |
| 2014-09-30 | $7.07M 10-Q · filed 2015-11-05 | $12.13M derived: sum of 2 quarters · filed 2015-11-05 | $15.13M 10-Q · filed 2015-11-05 | $18.86M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | $5.06M 10-Q · filed 2015-08-10 | $8.06M 10-Q · filed 2015-08-10 | $11.79M derived: sum of 3 quarters · filed 2016-02-26 | $15.45M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | $3.00M 10-Q · filed 2015-05-11 | $6.73M derived: sum of 2 quarters · filed 2016-02-26 | $10.39M derived: sum of 3 quarters · filed 2016-02-26 | $13.84M derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | $3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $7.39M derived: sum of 2 quarters · filed 2016-02-26 | $10.84M derived: sum of 3 quarters · filed 2016-02-26 | $13.33M 10-K · filed 2016-02-26 |
| 2013-09-30 | $3.66M 10-Q · filed 2014-11-10 | $7.11M derived: sum of 2 quarters · filed 2014-11-10 | $9.60M 10-Q · filed 2014-11-10 | |
| 2013-06-30 | $3.44M 10-Q · filed 2014-08-07 | $5.94M 10-Q · filed 2014-08-07 | ||
| 2012-12-31 | $7.21M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |